IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

Acute ST Elevation In Myocardial Infraction

1Shweta umakant mandle, 2Shravani madhukarrao chatte, 3Pradnya upendra chikurtikar, 4Vanita wadewale

1Student , 2Student , 3Student , 4Assistant professor

1Srtmu University, nanded ,

2Srtmu University, nanded,

3Srtmu University, nanded ,

4Srtmu, University, nanded

Abstract

Acute ST elevated myocardial infraction is mainly associated with the complete impediment of the coronary arteries. As we extensively seen that myocardial infraction is the main cause of death. Specifically exposure occur in MI is due to abnormal lipids, vegetation of infective endocarditis, unhealthy lifestyle, vasospasm. The troponin biomarker can be used to identify cardiac damage in MI patients. The necrosis that develops when the blood supply to the heart is reduced to a minimum indicates myocardial infarction. A crucial diagnostic technique for identifying MI is the electrocardiogram (ECG). About ¼ patients die before the therapy can be instituted. The main objective of acute care for patients with STEMI is to quickly restore blood flow using reperfusion therapy (percutaneous coronary intervention, fibrinolysis) to the acutely occluded coronary artery. The primary percutaneous coronary intervention with or without stent placement is the procedure of choice for all STEMI. A considerable portion of patients get heart failure due to diminished left ventricular function, which can raise long-term mortality and morbidity.

Keywords

Percutaneous intervention, thrombolytic therapy, coronary artery, ST segment elevated myocardial infraction

Introduction

Myocardial infarction (MI), also referred to as a "heart attack," is brought on by a partial or total interruption of blood supply to the myocardium. Myocardial infarction can be "silent," go undiagnosed, or it can be a catastrophic occurrence that results in hemodynamic decline and untimely death. Despite recent advancements, disputes still exist on the best way to treat ST segment elevation myocardial infraction, which continues to be a leading cause of premature mortality globally. It often happens when a plaque that has ruptured or degraded blocks a coronary artery by thrombotic occlusion. Characteristic symptoms and ECG alterations are used to make the diagnosis, which is then confirmed by elevated cardiac enzyme levels. Fibrinolytics are an alternative first line approach to emergency percutaneous coronary intervention with stent placement. Recanalization of the thrombosis coronary artery has been 50-90% cases.



Plaque rupture with abrupt onset is possible in patients with coronary atherosclerosis and high-risk thin cap fibroatheroma (TCFA)[. This causes alterations in the vascular endothelium, which set off a chain reaction of platelet adhesion, activation, and aggregation [8], leading to the development of thrombosis. Plaque rupture with abrupt onset is possible in patients with coronary atherosclerosis and high-risk thin cap fibroatheroma (TCFA)[7]. This causes alterations in the vascular endothelium, which set off a chain reaction of platelet adhesion, activation, and aggregation , leading to the development of thrombosis. the risk of recurrent adverse cardiovascular events remains substantial and may vary significantly across different subgroups of STEMI patients [3], justifying the continued efforts to improve the quality of care. Thrombolytic therapy has been shown to reduce mortality in patients with STEMI. Thrombolytics are contraindicated in patients with non–ST elevation MI because no clinical benefit has been shown and unwarranted risks exist.

The part that percutaneous coronary intervention: A critical role in patients with st segment elevated mi

Percutaneous coronary intervention (PCI), also known as coronary angioplasty, is a nonsurgical technique for treating obstructive coronary artery disease, including unstable angina, acute myocardial infarction (MI), and multivessel coronary artery disease (CAD).

The purpose of percutaneous coronary intervention (PCI), a non-surgical, invasive treatment, is to reduce coronary artery constriction or blockage and enhance blood flow to the ischemic region. This is typically accomplished using a variety of techniques, the most popular being inflating the restricted area or inserting a stent to keep the artery open. This activity explains the justifications for PCI and emphasizes the function of the multidisciplinary team in the treatment of CAD patients.



Percutaneous femoral, radial, or brachial artery punctures are used to perform the PTCA procedure. Because it lessens patient discomfort, improves time to ambulation, and lowers the likelihood of some problems (such as hemorrhage and pseudoaneurysm formation), the radial technique is becoming more and more popular.

A guiding catheter is threaded to the proper coronary ostium after being placed into a significant peripheral artery. The atherosclerotic plaque is dislodged, and the artery is dilated using a balloon-tipped catheter that is positioned within the stenosis and guided by fluoroscopy or intravascular ultrasonography. A further angiogram is performed following the surgery to record any changes. As needed, the surgery is frequently carried out in two or three vessels.

objectives

- Give examples of percutaneous coronary intervention indications.
- Describe the percutaneous coronary intervention procedure.
- List all of the risks associated with percutaneous coronary intervention.
- Give examples of how the interprofessional team's care coordination has to be improved in order to improve the care given to PCI patients.

Stents

Expandable wire mesh cylinders called stenting are used to hold stenotic portions of coronary arteries open. Stents work best when

1. Large native coronary arteries with short lesions that have not been previously treated with PTCA
2. In saphenous vein grafts, focal lesions
3. PTCA treatment for abrupt closure

Anticoagulation and supplemental treatment

To lower the likelihood of thrombosis at the site of balloon dilation, several anticoagulant and antiplatelet regimens are administered both during and after angioplasty. Patients with unstable non-ST-segment elevation myocardial infarction typically get Thienopyridines (clopidogrel, prasugrel, ticagrelor) and glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban) as standard of therapy. Thienopyridines are continued for at least 6 to 12 months after PCI to reduce the risk of in-stent thrombosis until endothelialization of the stent has taken place (frequently in combination with aspirin). To lower the risk of coronary spasm, calcium channel blockers and nitrates may also be used.

Diagnostic criteria: -

(I) Chest pain with no known etiology.
(II) Myocardial infraction with certainty the diagnosis is certain.
(III) Check for myocardial infarction if you have chest pain differentiating factors: just the cardiovascular system.
(IV) further signs: tests were requested however chest discomfort was not the main symptoms.



Acute myocardial infarction-compatible symptoms that are accompanied by both clear myocardial infarction-related alterations in the electrocardiogram and increases in both of the two cardiac enzymes lactate dehydrogenase and creatine phosphokinase to levels above twice the upper limit of normal.

Possible myocardial infarction is defined as having symptoms consistent with an acute myocardial infarction as well as either clear ECG alterations indicative of myocardial infarction or increases in cardiac enzyme levels beyond twice the upper limit of normal.

Myocardial infarction may have occurred if there were symptoms consistent with acute myocardial infarction and either an abnormal ECG (which is not typical of myocardial infarction) or an abnormal elevation in cardiac enzyme that was less than twice the upper limit of normal

Thrombolytic therapy

Acute ST-elevation MI (STEMI) is frequently the clinical result when thrombosis causes complete blockage of blood flow. Acute STEMI patients should receive coronary reperfusion treatment using either fibrinolysis or primary percutaneous coronary intervention (PCI). A kind of thrombolytic therapy known as fibrinolysis includes the injection of medications that disintegrate blood clots. Faster blood flow restoration to the heart muscle is the aim of fibrinolysis. Recurrent myocardial infarction, stroke, and death are all reduced in STEMI patients who get fibrinolytic treatment. It is crucial to remember that fibrinolytic treatment has some restrictions and potential drawbacks. The decision between primary PCI and fibrinolysis is based on several variables, including the amount of time.

These medications belong to the plasminogen activator class. Acute peripheral artery occlusion, deep vein thrombosis, pulmonary embolism, acute ischemic stroke, intracardiac thrombus development, and acute myocardial infarction are all treated with this class of medication. The use, mechanism, and limitations of thrombolytics are discussed in this activity. When treating patients with intravascular clots such as those with acute myocardial infarction, acute ischemic stroke, and other disorders, this exercise will also emphasise the mechanism of action, adverse event profile, monitoring, and toxicity important for interprofessional team members. The intra-coronary use of a glycoprotein IIb/IIIa antagonist can reduce infarct size. Pre- and post-conditioning techniques can provide additional cardio protection.

Time lag in starting in the infusion is critical for reducing area of necrosis preserving ventricular function and mortality. The benefits of iv thrombolytic therapy have been establish by large, randomized studies aspirin with or without heparin generally starts concurrently or soon after thrombolysis to prevent reocculsion.

The following are significant variables that affect the reperfusion technique selection:

a) Time between the initial medical encounter and the start of PCI.
b) Duration of symptoms before presentation.
c) Diagnostic ambiguity.
d) Conditions that preclude PCI or fibrinolysis.
e) Factors at high risk that Favour no reperfusion.

Risk assessment in patient with st elevated segment in myocardial infraction

One of the main causes of mortality and morbidity worldwide is ST-elevation myocardial infarction (STEMI).Clinical traits like age and the presence of comorbidities have an impact on STEMI. Growing older and having concomitant conditions have been identified as important indicators of clinical prognosis in STEMI patients. Existing coronary heart disease, diabetes mellitus, renal disease, peripheral vascular disease, and heart failure are comorbidities that increase the risk of early mortality. Growing older and having concomitant conditions have been identified as important indicators of clinical prognosis in STEMI patients. Existing coronary heart disease, diabetes, kidney disease, peripheral vascular disease, and heart failure are among the comorbidities that increase the risk of early mortality. emergency medical care Increasing patient access to

instruments like the ECG, chest x-ray, and echocardiography can provide more data, furthering the risk stratification of patients.

the presence of rupture-prone atheroma plaques [8]. Biomarkers of myocardial injury are used to determine the short- and long-term risk of STEMI patients in addition to coronarography lesions and the outcome of their therapy.

Recommendations associated with the myocardial infraction

- Initial evaluation - All patients with suspected acute coronary syndrome (ACS) should undergo an initial evaluation to quickly confirm or rule out the presence of STEMI and to find out if there are any additional conditions that might modify their course of treatment.
- quick diagnosis - The quick diagnosis of STEMI does not require evidence of increased cardiac biomarkers like troponin; it simply requires the presence of symptoms suggestive for an ACS and a confirmed ECG.
- Monitoring and testing should be used to identify conditions that pose a life-threatening threat or materially modify the standard management of STEMI.
- Assessment of potentially fatal conditions - The initial evaluation of patients with STEMI includes a quick check for problems that need additional care or change how STEMI therapy is administered.

Stent technology advances with primary percutaneous intervention

Since using bare-metal stents (BMS) during primary PCI reduces the rates of reinfarction and target vessel revascularization but not death, it has become standard practice.

Drug-eluting stents (DES) have increasingly surpassed BMS in recent years for both primary and elective PCI because they considerably lower restenosis rates and the necessity for reintervention. When compared to BMS, first-generation DES like Taxus and Cypher have been shown to increase the risk of fatal outcomes and very late stent thrombosis with MI, especially in individuals with large DES.

There was no longer a risk increase for acute or late stent thrombosis when the newer generation of DES, such as Xience, Promeus, and Endeavour, was compared with BMS. By combining bioresorbable vascular scaffolds with DES, persistent inflexible metallic structures in coronary arteries may be avoided.

STEMI stent implantation in patients taking oral anticoagulation and presenting with STEMI constitutes a significant challenge as it results in triple therapy, which significantly increases the risk of major bleedings. Bioresorbable vascular scaffolds have been shown to be safe and effective in chronic stable coronary artery disease as well as in STEMI.
According to a recent study, the risk of stent thrombosis was not affected by the use of warfarin plus clopidogrel during primary PCI compared to warfarin, clopidogrel, and aspirin.

There are mainly two types of risk factors including modifiable and non-modifiable risk factors.



Modifiable risk factors-

I. Smoking: Smoking is a significant risk factor for sudden cardiac mortality, atherosclerosis, and myocardial infarction. Smoking causes early STEMI, especially in people who are otherwise healthy. Smokers have infarction on average 7 years early and more than twice as frequently as non-smokers.

II. Physical activity: MI is more likely to occur in those with numerous cardiac risk factors who are inactive. These people should start with basic exercise training in order to benefit. Before engaging in intense activity, rigorous risk factor adjustment is required.

III. Triglyceride and LDL levels: The predisposing risk factors for MI are high triglyceride levels and dense, tiny LDL particles. Non-fasting triglyceride levels, particularly when the total cholesterol level is also increased, seem to be a reliable and independent predictor of future risk of MI. The cause of it is that elevated triglyceride levels and low HDL-C levels disturb metabolism, which has unfavorable effects. Elevated triglyceride levels might be used to identify high-risk patients.

IV. Obesity/BMI: An increase in BMI is closely associated to the incidence of MI.Extreme obesity increases the likelihood of infarction since it is a known risk factor for MI. To lessen the population burden of MI in the United States, measures to promote healthy body weight are being developed.

V. Diabetes mellitus (DM): When all diabetic and non-diabetic individuals were compared to the control group, significant differences in the parameters examined were found. With regard to some risk factors, such as age, hypertension, and hypertriglyceridemia in diabetic patients, while smoking and family history are predominate in non-diabetic patients, it was discovered that there are significant differences between diabetic and non-diabetic patients in men who have myocardial infarction. The risk profiles of newly diagnosed diabetic males, however, are comparable to those of their known diabetic counterparts.

VI. Hypertension: A significant, independent risk factor for MI. A heart attack or MI can develop from atherosclerosis in the coronary blood arteries, which is a major risk factor. MI and hypertension have a tight relationship.

VII. Psychosocial stress : Chronic life stress, social isolation, and anxiety all raise the risk of heart attack and stroke due to psychosocial stress.

Non modifiable risk factors:

1. according to the age factor - (age between 50 to 60 yrs) are more predisposed to cardiovascular diseases than young people.
2. Gender - Mens are more susceptible than women. In women generally after menopause heart related complications occur due to abnormility in lipid levels.
3. Genetic factors - The risk of cardiovascular disease is increased in people who had family history of coronary heart diseases or stroke.

Coronary artery bypass graft (CABG): -

During the acute and subacute phases of STEMI, coronary artery bypass grafting (CABG) is performed.5,6 CABG is sometimes employed as the primary reperfusion modality, either in the acute phase or after initial stabilization, in patients with a coronary architecture unsuitable for PCI. The majority of patients have CABG following PCI as a final or supplementary revascularization. When there is substantial coronary artery stenosis, coronary artery bypass grafting (CABG) can restore a sufficient blood flow to myocardial blood supply areas (1). CABG is still a safe and practical option for patients with acute coronary syndrome, despite the fact that PCI has replaced it as the primary intervention procedure for acute myocardial infarction (AMI). In most hospital settings, primary percutaneous coronary intervention and fibrinolysis are preferable to coronary artery bypass graft surgery (CABG) because they may both reopen an acutely blocked coronary artery in a fraction of the time. In some acute MI situations, CABG may be preferred. Patients with complicated coronary architecture and no longer showing symptoms of active ischemia may benefit more from CABG. Even in an emergency, clinical considerations including diabetes and impaired ventricular function are reasons to choose CABG over PCI. The choice of modality should be made specifically for each patient and may depend on the accessibility of surgical facilities in the area.

The benefit of CABG is that total revascularization can be accomplished rather of just focusing on the offending lesion, even in an urgent situation. er single thoracic artery and multiple vein conduits. CABG with arterial grafts can improve patient longevity, particularly with appropriate patient and coronary artery target selection

Less-invasive strategies are emerging. general, CABG is preferred over percutaneous coronary intervention in patients with a heavy atherosclerotic burden and diabetes, and those without multiple significant baseline comorbidities, frailty, or short life expectancy.

Guideline-directed medical therapy in coronary artery disease is essential for improved outcomes in primary and secondary prevention. For more than 50 years, coronary artery bypass grafting (CABG) has been carried out. Additionally, even though older and higher-risk patients are using the surgery more frequently, the results have significantly improved with time. The utilization of a diverse, skilled heart team approach has become crucial as the procedure has advanced beyond a "cookie-cutter" generic cardiac operation.

Why is it necessary in mi patient?

Current guidelines recommend CABG over PCI for multivessel coronary artery disease in patients with diabetes and for those with left ventricular dysfunction. Even for severe left ventricular dysfunction (ejection fraction < 35%), CABG is associated with improved long-term outcomes, including survival, compared with PCI for patients with indications for CABG and who can tolerate the stress of surgery.

Why CABG improves outcomes for left main and multivessel coronary artery disease is likely multifactorial. The distal insertion of a bypass graft is downstream from where most future atherosclerotic disease might develop.

Other therapies

- Oxygenation- In MI patients oxygen inhalation is mostly important to stabilize the patient and maintain O_2 level.
- Maintenance of blood volume, tissue perfusion and microcirculation-
- To maintain blood volume, tissue perfusion and microcirculation, a steady intravenous infusion of saline or low molecular weight dextran is given.
- ACE inhibitors cause both arteriolar and Veno dilation in chronic heart failure patient. ACE inhibitors reduces episodes of decompensation MI and sudden death.
- Several mega trials have established oral ACE inhibitors administered while MI is evolve in and continue for 6 weeks to reduce as well as long term mortality.
- Beta blockers used early in evoving MI can reduce the infract size and further complications.
- Thrombolysis and reperfusion- Fibrinolytic agents like streptokinase, alteplase to achieve the reperfusion of infracted area still thrombolysis can be started within 1-2 hrs of MI symptoms.

Conclusion:

As per our study, Complete revascularization in patients with acute MI and MV CAD should be considered during index PCI or during a staged procedure where possible and suitable. Because of their well-documented ability to reduce death rates, thrombolytic medicines have earned a place in the treatment of AMI. In general, comparative trials have revealed very minor differences in efficacy among these medicines. Such developments are likely to improve the already significant mortality and morbidity reductions associated with PPCI. Acute STEMI patients are at risk of problems both immediately and in the long run.

Clinical judgement and readily available tools, including The ECG, chest x-ray, and echocardiogram, remain standard for care testing during an emergency. Coronary artery bypass surgery remains an established form of treatment for coronary artery disease, and the majority of coronary surgical procedures are performed for multiple vessel disease. Overall, the mortality rate of coronary artery surgery is low, at around 2%–3%. CABG outcomes have traditionally been characterized in terms of mortality and morbidity; nevertheless, CABG adjustment is a complex phenomenon that cannot be entirely explained by medical considerations. Survivors of an acute MI should receive cardiac rehabilitation and be closely monitored to ensure adequate risk factor

modification and optimization (and adherence to) pharmacotherapy for secondary prevention, as well as to monitor for the development of post-MI complications and/or residual angina symptoms.

Reference

Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000 Sep;36(3):959-69. [PubMed]

Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD., ESC Scientific Document Group. Fourth universal definition of myocardial infarction (2018). Eur Heart J. 2019 Jan 14;40(3):237-269. [PubMed]

1Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J. Factors of risk in the development of coronary heart disease—six year follow-up experience. The Framingham Study. **Ann Intern Med**. 1961; 55:33–50.CrossrefMedlineGoogle Scholar

2Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. **Circulation**. 1998; 97:1837–1847.LinkGoogle Scholar

Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003 Jan 04;361(9351):13-20. [PubMed]

Andersen HR, Nielsen TT, Vesterlund T, Grande P, Abildgaard U, Thayssen P, Pedersen F, Mortensen LS., DANAMI-2 Investigators. Danish multicenter randomized study on fibrinolytic therapy versus acute coronary angioplasty in acute myocardial infarction: rationale and design of the DANish trial in Acute Myocardial Infarction-2 (DANAMI-2). Am Heart J. 2003 Aug;146(2):234-41. [PubMed]

Nygaard RM, Lacey AM, Lemere A, Dole M, Gayken JR, Lambert Wagner AL, Fey RM. Time Matters in Severe Frostbite: Assessment of Limb/Digit Salvage on the Individual Patient Level. J Burn Care Res. 2017 Jan/Feb;38(1):53-59. [PubMed]
2.

Castillo-Perez M, Jerjes-Sánchez C, Rodríguez D, Paredes-Vazquez JG, Panneflek J, Vazquez-Guajardo M. Clinical outcomes of very elderly patients treated with ultrasound-assisted catheter-directed thrombolysis for pulmonary embolism: a systematic review. J Thromb Thrombolysis. 2021 Jul;52(1):260-271. [PubMed]
3.

Edwards Z, Nagalli S. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): May 9, 2023. Streptokinase. [PubMed]
4.

Reed M, Kerndt CC, Nicolas D. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): May 16, 2023. Alteplase. [PubMed]

Dawber TR. The Framingham Study: The epidemiology of atherosclerotic disease. Cambridge, MA, *Harvard University Press*, 1980.

Mendis S. The contribution of the Framingham Heart Study to the prevention of cardiovascular disease: A global perspective. Progress in *Cardiovascular Diseases* 2010;53(1):10-14.

Tunstall-Pedoe H, ed. World largest study of heart disease, stroke, risk factors and population trends, 1979-2002. MONICA Monograph and Multimedia Sourcebook, MONICA Project. Geneva, World Health Organization, 2003.

Yusuf S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. *Lancet* 2004;364(9438):937-952.

Shabiir M, Kayani AM, Qureshi O, Mughal MM. Predictor of fatal outcome in acute myocardial infarction. Jounal ayub med college abbotabad 2008:20(3):14-6

Hashmi, K.A., Abbas, K., Hashmi, A.A. et al.In-hospital mortality of patients with cardiogenic shock after acute myocardial infarction; impact of early revascularization.

influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI).

Nigwekar SU, Kandula P, Hix JK, Thakar CV. Off-pump coronary artery bypass surgery and acute kidney injury: a meta-analysis of randomized and observational studies. Am J Kidney Dis. 2009 Sep;54(3):413-23. [PubMed]

Shumacker HB. *The Evolution of Cardiac Surgery.* Bloomington, Ind, USA: Indiana University Press; 1992. [Google Scholar].

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5985500/

Myocardial infarction redefined – a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction.